Articles with public access mandates - Pierosandro TagliaferriLearn more
Not available anywhere: 7
Mir-221/222 are promising targets for innovative anticancer therapy
MT Di Martino, M Rossi, D Caracciolo, A Gullà, P Tagliaferri, P Tassone
Expert Opinion on Therapeutic Targets 20 (9), 1099-1108, 2016
Mandates: US National Institutes of Health
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma
M Rossi, E Altomare, C Botta, ME Gallo Cantafio, S Sarvide, D Caracciolo, ...
Leukemia 35 (3), 823-834, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine
R Catalano, R Rocca, G Juli, G Costa, A Maruca, A Artese, D Caracciolo, ...
European Journal of Medicinal Chemistry 183, 111715, 2019
Mandates: European Commission, AIRC Foundation for Cancer Research in Italy
Error‐prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment
D Caracciolo, C Riillo, M Arbitrio, MT Di Martino, P Tagliaferri, P Tassone
International journal of cancer 147 (10), 2658-2668, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Impact of natural dietary agents on multiple myeloma prevention and treatment: Molecular insights and potential for clinical translation
L Raimondi, A De Luca, G Giavaresi, A Barone, P Tagliaferri, P Tassone, ...
Current Medicinal Chemistry 27 (2), 187-215, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS
S Franzoni, L Morbioli, A Turtoro, L Solazzo, A Greco, M Arbitrio, ...
Journal of Pharmaceutical and Biomedical Analysis 188, 113451, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Overall Survival Analyzer: A software tool to analyze genotyping and clinical data enriched with temporal events
G Agapito, PH Guzzi, C Botta, M Arbitrio, P Tassone, P Tagliaferri, ...
2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM …, 2015
Mandates: Government of Italy
Available somewhere: 49
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ...
Clinical cancer research 18 (22), 6260-6270, 2012
Mandates: US National Institutes of Health
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy
P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ...
Journal of immunotherapy 33 (4), 435-441, 2010
Mandates: US National Institutes of Health
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullà, M Rossi, ...
Clinical Cancer Research 19 (8), 2096-2106, 2013
Mandates: US National Institutes of Health
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ...
Leukemia 32 (9), 1948-1957, 2018
Mandates: US National Institutes of Health, US Department of Veterans Affairs
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ...
Cell death & disease 3 (11), e436-e436, 2012
Mandates: US National Institutes of Health
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic “dark matter”
K Grillone, C Riillo, F Scionti, R Rocca, G Tradigo, PH Guzzi, S Alcaro, ...
Journal of Experimental & Clinical Cancer Research 39, 1-19, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ...
Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012
Mandates: US National Institutes of Health
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma
MT Di Martino, V Campani, G Misso, ME Gallo Cantafio, A Gulla, ...
PloS one 9 (2), e90005, 2014
Mandates: Government of Italy
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells
T Calimeri, E Battista, F Conforti, P Neri, MT Di Martino, M Rossi, ...
Leukemia 25 (4), 707-711, 2011
Mandates: US National Institutes of Health
Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma
N Amodio, MA Stamato, AM Gullà, E Morelli, E Romeo, L Raimondi, ...
Molecular cancer therapeutics 15 (6), 1364-1375, 2016
Mandates: US National Institutes of Health, US Department of Veterans Affairs
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ...
Leukemia 29 (11), 2173-2183, 2015
Mandates: US National Institutes of Health, US Department of Veterans Affairs
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells
A Gulla, MT Di Martino, ME Gallo Cantafio, E Morelli, N Amodio, C Botta, ...
Clinical cancer research 22 (5), 1222-1233, 2016
Mandates: US National Institutes of Health, US Department of Veterans Affairs
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
A Gullà, T Hideshima, G Bianchi, M Fulciniti, M Kemal Samur, J Qi, YT Tai, ...
Leukemia 32 (4), 996-1002, 2018
Mandates: US National Institutes of Health, US Department of Veterans Affairs
Publication and funding information is determined automatically by a computer program